Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.34
    -0.43 (-5.53%)

    Market Cap: $401.70M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Puma Biotechnology Inc (PBYI) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Puma Biotechnology (PBYI) trades at 15.0x trailing earnings and 1.6x sales. Its P/E of 15.0x is above its 5-year median of 9.9x. Its forward P/E is 3.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 328.6% higher over the next year.

    MultipleValue
    P/E (trailing)15.0x
    Forward P/E3.5x
    Price to sales1.6x
    Price to book2.6x
    EV/EBITDA9.2x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 33.3% above 1.2x and its P/B is 60.6% below 6.6x.

    MultipleCurrent5-year median10-year median
    P/E15.0x9.9xN/A
    P/S1.6x0.7x1.2x
    P/B2.6x3.3x6.6x
    Medians of month-end values through Oct 2026: 50 to 60 months (5-year) and 108 to 110 months (10-year).

    Valuation History

    Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 3.9x in 2024 to 21.1x in 2022.

    Year endPriceP/EP/SP/B
    2025$5.959.2x1.3x2.4x
    2024$3.053.9x0.6x1.6x
    2023$4.337.0x0.9x3.9x
    2022$4.2321.1x0.9x9.0x
    2021$3.04N/A0.5xN/A
    2020$10.26N/A1.8xN/A
    2019$8.75N/A1.2x19.6x
    2018$20.35N/A3.1x22.7x
    2017$98.85N/A133.8x69.6x
    2016$30.70N/AN/A5.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PBYI

    What is PBYI's forward P/E ratio?

    Puma Biotechnology has a forward P/E ratio of 3.5x.

    Is PBYI stock overvalued?

    GNG's valuation label for PBYI is Overvalued.

    What is PBYI's price to sales ratio?

    Puma Biotechnology has a price to sales ratio of 1.6x.

    What is Puma Biotechnology's average P/E ratio over 5 years?

    Puma Biotechnology's median P/E over the last 5 years is 9.9x, from 50 month-end values through Oct 2026.